Evidence map›Paper›PMID 26654125›Full record

Trial reportEuropean urology2016

Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial.

Jill M Hamilton-Reeves, Misty D Bechtel, Lauren K Hand, Amy Schleper, Thomas M Yankee, Prabhakar Chalise, Eugene K Lee, Moben Mirza, Hadley Wyre, Joshua Griffin and 1 more

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 45 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 5 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01868087 early_phase1completednot on this map

Impact Advanced Recovery® for Radical Cystectomy (RC) Patients

TypeinterventionalSponsorJill Hamilton-Reeves, PhD RD LDRan2013 to 2016Enrolled30ConditionsBladder Cancer, Radical Cystectomy, Urinary Bladder Neoplasms, SurgeryArmsBoost Plus®, Impact Advanced Recovery®
NCT06002269 nacompletednot on this mapstarted 2024, after this paper: background citation

A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients: the BOOST Study

TypeinterventionalSponsorUniversity of UtahRan2024 to 2025Enrolled8ConditionsBladder Cancer, Cystectomy, ChemotherapyArmsDietary and Exercise Intervention
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2023
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jill M Hamilton-ReevesDepartment of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: jhamilton-reeves@kumc.edu.
Misty D BechtelDepartment of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.
Lauren K HandDepartment of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.
Amy SchleperDepartment of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.
Thomas M YankeeDepartment of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City, KS, USA.
Prabhakar ChaliseDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
Eugene K LeeDepartment of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
Moben MirzaDepartment of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
Hadley WyreDepartment of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
Joshua GriffinDepartment of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
Jeffrey M HolzbeierleinDepartment of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
University of Kansas Medical Center · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Heartland Institute for Clinical and Translational ResearchKL2TR000119 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BAROHN, RICHARD J. · 2012 to 2015
$2.5M
NCATS NIH HHS KL2 TR000119NCATS NIH HHS KL2 TR000119-04NCI NIH HHS P30 CA168524
6 · The paper itself

Abstract

unlabelledAfter radical cystectomy (RC), patients are at risk for complications including infections. The expansion of myeloid-derived suppressor cells (MDSCs) after surgery may contribute to the lower resistance to infection. Immune response and postoperative complications were compared in men consuming either specialized immunonutrition (SIM; n=14) or an oral nutrition supplement (ONS; n=15) before and after RC. MDSC count (Lin- CD11b+ CD33+) was significantly different between the groups over time (p=0.005) and significantly lower in SIM 2 d after RC (p<0.001). MDSC count expansion from surgery to 2 d after RC showed a weak association with an increase in infection rate 90 d after surgery (p=0.061). Neutrophil:lymphocyte ratio was significantly lower in SIM compared with ONS 3h after the first incision (p=0.039). Participants receiving SIM had a 33% reduction in postoperative complication rate (95% confidence interval [CI], 1-64; p=0.060) and a 39% reduction in infection rate (95% CI, 8-70; p=0.027) during late-phase recovery. The small sample size limits the study findings. PATIENT SUMMARY: Results show that the immune response to surgery and late infection rates differ between radical cystectomy patients receiving specialized immunonutrition versus oral nutrition supplement in the perioperative period.

trial registrationClinicalTrials.gov NCT01868087.

Indexed as

Immunocompromised HostNutritional StatusAgedCD11b AntigenCell ProliferationCystectomyEnteral NutritionFood, FormulatedHumansKansasMaleMiddle AgedMyeloid CellsNutritive ValuePhenotypePilot ProjectsCD11b AntigenCD33 protein, humanSialic Acid Binding Ig-like Lectin 3ArginineBladder cancerFish oilMyeloid-derived suppressor cellsNeutrophil:lymphocyte ratioPG-SGARadical cystectomy

Identifiers

PMID26654125
PMCPMC4793712
OpenAlexW2184087537

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.